Opinion|Videos|January 21, 2025
ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL
Panelists discuss how pirtobrutinib plus venetoclax and obinutuzumab shows promise as a frontline chronic lymphocytic leukemia (CLL) treatment option, with its high selectivity and favorable safety profile potentially offering advantages over current Bruton tyrosine kinase inhibitor–based regimens, though more long-term data is needed to determine its optimal place in therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Another frontline triplet regimen being studied is how pirtobrutinib plus venetoclax and obinutuzumab. What are your thoughts on this combination, and do you foresee a place in therapy for it in the frontline setting?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5